Observational studyRheumatology (Oxford, England)2025

Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases.

Ana Martínez-Feito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.